MCT8 deficiency: extrapyramidal symptoms and delayed myelination as prominent features.
Davide Tonduti, Adeline Vanderver, Angela Berardinelli...
https://pubmed.ncbi.nlm.nih.gov/22805248/Actively Recruiting
Led by Charite University, Berlin, Germany · Updated on 2024-08-22
200
Participants Needed
1
Research Sites
2 weeks
Total Duration
Researchers are investigating thyroid hormone resistance caused by mutations in the thyroid hormone transporter MCT8 or the thyroid hormone receptor alpha THR, conditions that affect brain development and function. These mutations can lead to severe intellectual disabilities, developmental delays, and movement disorders despite normal thyroid hormone production. The study aims to improve diagnosis by using the serum free T3free T4 ratio as a screening tool and to explore genetic regulation and mutations contributing to thyroid hormone resistance. This observational registry study, called DEEPTYPE, collects detailed retrospective and prospective clinical data from patients with coding or non-coding mutations in the SLC16A2 or THRA genes. The registry identifies patients with milder symptoms or non-coding mutations and groups patients based on their genetic profiles. There is no intervention or treatment involved the study focuses on documenting and understanding the full spectrum of these conditions. Participants will have their neurological development, motor skills, and body measurements tracked over a period of five years. Researchers will assess various clinical and biochemical markers, including thyroid hormone levels, response to therapies, cerebrospinal fluid components, and movement disorder evaluations. This comprehensive monitoring aims to characterize the clinical features and progression of thyroid hormone resistance, supporting future clinical trial readiness and improved patient care.
CONDITIONS
Register for Patients With Thyroid Hormone Resistance.
N
Nina-Maria Wilpert
M
Markus Schülke-Gerstenfeld, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Charite University, Berlin, Germany
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants who undergo routine care are observed and clinical data are collected retrospectively and prospectively to understand the genotypic and phenotypic spectrum of thyroid hormone resistance.
Visits as needed for routine clinical assessments
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Davide Tonduti, Adeline Vanderver, Angela Berardinelli...
https://pubmed.ncbi.nlm.nih.gov/22805248/Nina-Maria Wilpert, Martin Krueger, Robert Opitz...
https://pubmed.ncbi.nlm.nih.gov/32143555/Edith C H Friesema, Annette Grueters, Heike Biebermann...
https://pubmed.ncbi.nlm.nih.gov/15488219/Nina-Maria Wilpert, Davide Tonduti, Ylenia Vaia...
https://pubmed.ncbi.nlm.nih.gov/37881807/Stefan Groeneweg, Ferdy S van Geest, Ayhan Abacı...
https://pubmed.ncbi.nlm.nih.gov/32559475/Stefan Groeneweg, Robin P Peeters, Carla Moran...
https://pubmed.ncbi.nlm.nih.gov/31377265/Ganaelle Remerand, Odile Boespflug-Tanguy, Davide Tonduti...
https://pubmed.ncbi.nlm.nih.gov/31410843/Silvia Masnada, Catherine Sarret, Clara Eleonora Antonello...
https://pubmed.ncbi.nlm.nih.gov/34969638/Charite University, Berlin, Germany
Lead Sponsor